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Abstract
Background: Canine osteosarcoma is clinically nearly identical to the human disease, but is common and highly
heritable, making genetic dissection feasible.
Results: Through genome-wide association analyses in three breeds (greyhounds, Rottweilers, and Irish wolfhounds),
we identify 33 inherited risk loci explaining 55% to 85% of phenotype variance in each breed. The greyhound locus
exhibiting the strongest association, located 150 kilobases upstream of the genes CDKN2A/B, is also the most rearranged
locus in canine osteosarcoma tumors. The top germline candidate variant is found at a >90% frequency in Rottweilers
and Irish wolfhounds, and alters an evolutionarily constrained element that we show has strong enhancer activity in
human osteosarcoma cells. In all three breeds, osteosarcoma-associated loci and regions of reduced heterozygosity are
enriched for genes in pathways connected to bone differentiation and growth. Several pathways, including one of
genes regulated by miR124, are also enriched for somatic copy-number changes in tumors.
Conclusions: Mapping a complex cancer in multiple dog breeds reveals a polygenic spectrum of germline risk factors
pointing to specific pathways as drivers of disease.
Background
Osteosarcoma (OS) is an aggressive cancer characterized
by early metastasis, primary onset in children and adoles-
cents, and high mortality rates (30% to 40%) [1]. Recent
work suggests that OS arises when osteoblast differenti-
ation from mesenchymal precursors is disrupted by gen-
etic or epigenetic factors [2]. While no structural variants
specific to OS have been identified, somatic alterations in
tumors are common and often affect suppressor genes
RB1, TP53, and the CDK4 inhibitors CDKN2A/B [2].
Germline mutations in RB1 and p53, two genes essential
for OS development, can increase disease risk [2-4]. The
only genome-wide association study (GWAS) of OS in
humans found two significant associations, one genic
(GRM4) and the other in a large gene desert, suggesting
inherited variation in regulatory elements underlies sus-
ceptibility [5].
OS in dogs is a spontaneously occurring disease with a
global tumor gene expression signature indistinguishable
from human pediatric tumors [6,7] and, while relative
age of onset is higher in dogs, their clinical progression
is remarkably similar [8]. Both human and canine OS
most commonly arise at the ends of the long bones of
the limbs and metastasize readily, usually to the lungs
[9]. Unlike human OS, canine OS is a highly heritable
disease with some large and giant dog breeds at >10× in-
creased risk, notably greyhounds (mortality from OS=
26%), Rottweilers (17%), and Irish wolfhounds (IWH,
21%) [10-12]. While size and hormonal factors influence
risk, variable rates among the larger size breeds suggest
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Kennel Club (AKC) registered dogs, a subpopulation that
tends to be taller than the racing dogs, has very low rates
of OS (G. Couto, unpublished observations).
Mapping disease genes using GWAS in dog breeds,
each effectively a genetic isolate only a few hundred
years old, requires approximately 10× fewer markers and
samples than in human populations [14]. However,
population structure, cryptic relatedness, and extensive
regions of near fixation in breeds complicate GWAS
analysis and to date, few studies have successfully mapped
risk factors for complex, multigenic diseases [15]. Here,
we use new methods for analyzing breed populations to
identify genomic loci associated with OS in the first multi-
breed association study of a highly polygenic canine disease.
We explain the majority of the OS phenotype variance in
three high-risk breeds, identify a common regulatory risk
factor, and reveal novel genes and pathways underlying
this poorly understood disease.
Results
Population genetics of GWAS dog breeds
We genotyped 334 greyhounds, 166 Rottweilers, and
174 IWH on the 170,000 SNP Illumina canine HD ar-
rays, removing SNPs with call rates <95%, and one dog
from each pair with the same phenotype and genetic re-
latedness >0.25, preferentially retaining younger cases
and older controls. The final dataset (169,010 SNPs) in-
cluded 267 racing greyhounds (153 affected (A) +114
unaffected (U)), 135 Rottweilers (80 A + 55 U), 141 IWH
(76 A + 65 U), and 19 AKC greyhounds. The ratio of fe-
males to males was approximately equal in cases and
controls in the greyhounds (0.72 and 0.75 for A and U)
and Rottweilers (1.11 and 1.04), and more skewed in
IWH (1.62 and 1.41).
The three breeds are visibly discrete genetic popula-
tions; the AKC greyhounds cluster near but distinct
from their racing brethren (Figure 1a). The racing grey-
hound population is the least inbred, likely reflecting a
large effective population size, (inbreeding coefficient θ=
0.11 +/− 0.02), followed by the Rottweilers (θ=0. 23+/ −
0.04), IWHs (θ=0. 25 +/ − 0.04), and AKC greyhounds
(0.30 +/− 0.07) (Figure 1b) [16]. While linkage disequilib-
rium in all breeds is long, as compared to human popula-
tions, it varies markedly by breed, with average r
2
dropping below 0.2 at 196 kb in the greyhounds, 632 kb in
the Rottweilers, and 1,533 kb in the IWH, suggesting
GWAS regions will be shortest in greyhound, facilitating
identification of associated functional elements in this
breed (Figure 1c).
GWAS identifies 33 regions associated with osteosarcoma
We tested for association between OS and germ-line
variants with minor allele frequency >0.05 in each of the
three breeds independently, controlling for cryptic re-
latedness and population structure using a mixed model
approach with the top principal component as a covari-
ate [18,19]. We identified all SNPs with either significant
association (exceeding 95% confidence intervals defined
empirically using 1,000 random phenotype permuta-
tions) or suggestive association (P<0.0005; Figure 2a-f;
Methods) and defined regions of association using link-
age disequilibrium (Table 1, Additional file 1: Figure S1).
The proportion of very young cases in our IWH dataset
allowed us to focus on the more powerful comparison of
young cases and older controls (Additional file 1: Figure S2;
28 affected <6 years old and 62 unaffected >6 years old).
Within each breed, associated regions (P<0.0005) ex-
plain the majority of the phenotype variance: 57% in the
greyhound (14 loci), 53% in the IWH (4 loci), and 85%
in the Rottweilers (15 loci) (Figure 2g, Additional file 1:
Figure S3). The overall genotype relative risk estimated
for each dog, based on the risk contributed by each
locus, shows a clear separation between cases and con-
trols in each breed (Figure 2h), even at more stringent
significance thresholds (Additional file 1: Figure S4).
None of the top scoring SNPs was strongly correlated
with sex in a genome-wide analysis (Additional file 1:
Table S1), and including sex as a covariate revealed no
new regions of strong association. Although earlier work
on monogenic traits in dogs suggested risk factors often
are shared between breeds [20], we see no overlap in
regions of association between the breeds and a meta-
analysis of the three breeds yielded no significant associ-
ations (Additional file 1: Figure S5). Three possible
explanations for this observation are: (1) cancer risk fac-
tors are abundant in the overall dog population and each
breed inherited different subsets; (2) we cannot detect
the shared associations in the other breeds at our
current sample sizes; and (3) the risk haplotypes are
fixed or nearly fixed in the other breeds, and thus un-
detectable by association.
We tested the top 33 GWAS regions for fixation of
the risk allele (frequency >0.95) in the other two breeds.
In eight regions, the risk haplotype is fixed in one of the
other two breeds, but in only one is it fixed in both: the
risk allele tagging the top greyhound locus (A=0.84,
U=0.65), on chromosome 11, is fixed in both Rottweilers
(0.97) and IWH (0.95) (Table 1). This haplotype occurs at
lower frequency in the AKC greyhounds (0.61) and in a
panel of 28 other breeds from a previously published data-
set (0.51% +/− 0.24) [17]. We sequenced the locus
(chr11:43.0-48.9 Mb ) in eight greyhound cases and
seven controls, and densely genotyped and imputed
180 greyhound cases and 115 controls (Figure 3a). This nar-
rowed the region of association to a 15 kb non-coding
region (chr11:44,390,633-44,406,002) near CDKN2A (en-
codes p16
INK4a and p14
ARF), CDKN2B (p15
INK4b), and
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(Figure 3a). Both CDKN2A and CDKN2B function as
cell cycle regulators and tumor suppressors.
The risk haplotype at 11q16 is syntenic to a non-
coding regulatory region on human chromosome 9p21
(Figure 3b), and the alignment between dog and human
includes DNase hypersensitivity sites and peaks of
H3K27 acetylation characteristic of active enhancers
(Figure 3c) [25,26]. The human 9p21 locus is deleted in
5% to 21% of human OS [27], the absence of p16INK4a
expression is correlated with decreased survival in
pediatric OS patients [28], and increased p16 expression
is predictive of better response to chemotherapy [29].
Thus, we hypothesized that the variant(s) carried on the
risk haplotype disrupts enhancer elements upstream of
the CDKN2A/B locus, thereby altering expression of one
or more genes in the region.
We assayed the risk haplotype for regions of enhancer
activity using renilla/firefly luciferase assays in the hu-
man OS U2OS cell line, tiling the region with seven
fragments that were PCR-amplified from human genomic
DNA (Figure 3c). Several fragments showed enhancer
activity, and one increased luciferase expression >30-fold
(Figure 3d). The only greyhound variant identified in this
fragment region, a SNP, is also the top associated variant
in the greyhound finemapping/imputation dataset (dog
chr11:44405676; human chr9:22,148,443, P =3×10
-8)
(Figure 3a,b) (Additional file 1: Table S2). Additional
genotyping validated the imputation (186 dogs geno-
typed; 98.9% concordance). While this position is strongly
constrained to a C or Tacross mammals, including wolves
[30], the OS risk allele, A, is found in 87% of greyhound
cases and 68% of greyhounds controls (Figure 3e). We
analyzed the locus with two different transcription
factor binding motif analysis tools, FIMO [31] and
TOMTOM [32]. Just one motif, for PAX5, was signifi-
cantly detected by both tools and was specific to the
non-risk allele (C), suggesting that the risk allele (A) will
disrupt binding (Figure 3f, Additional file 1: Figure S6).
PAX5 regulates both B-cell and osteoblast differentiation
and bone formation [33,34].
We tested for association of chr11:44405676 to osteo-
sarcoma in eight more breeds with high rates of OS. We
found the greyhound risk allele at very high frequency in
the two other GWAS breeds, Rottweilers (92A +77U,
FA=0.98, FU =0 . 9 7) an d I WH (2 7 A+3 1U , F A =0.93,
FU = 0.92), with the risk allele slightly more common in
cases, and correlated with OS in Leonbergers (30A+25U,
FA=0. 77 , F U=0. 62 , P=0.09) and great Pyrenees (16A+
21U, FA=0. 78 , F U=0.6 2, P=0.14 ). An al yzed to ge th er ,
these four breeds replicate the association seen in the
greyhounds (pCMH=0.03, pCMH=2×10
-8 with greyhounds
included) and no odds-ratio heterogeneity was seen
between breeds (pBreslow-Day = 0.51) (Additional file 1:
Table S3) [35]. We found no association with OS risk in
mastiffs, Labrador retrievers, great Danes, and golden
retrievers. Although small samples limit statistical power,
these results suggest the effect of the risk variant may
depend on the genetic background in each breed. Pooled
sequencing data from an earlier project [30] show that the
OS risk allele (A) is never seen in wolves but is common in
purebred dogs (approximately 50%). The syntenic human
locus at 9p21 has one of the densest known concentrations
of regulatory elements in the human genome [36]. Breed-
specific variation in nearby functional elements may
modulate the effect of the chr11:44405676 variant.
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Figure 1 The three GWAS breeds (high risk of OS) and the AKC greyhounds (low risk of OS) are genetically distinct and highly inbred
populations. (a) Along the top two principal components of variation, the three breeds (Rottweilers (n=135, red), Irish wolfhounds (IWH, n=141,
purple), and racing greyhounds (n=267, dark blue) ) are each tight clusters equidistant apart, with the AKC subpopulation of greyhounds (n=19,
light blue) near but not overlapping the racing dogs. (b) Estimate of the inbreeding coefficient (IC) shows the racing greyhounds as the least
inbred, on average, while the other three populations fall within the range seen in an earlier survey of 28 dog breeds (grey bars mark average IC
in breed; two outliers at 0.53 and 0.62 not shown) [17]. (c) The extent of linkage disequilibrium, measured as average pair-wise r
2, drops below
0.2 at 196 kb, 632 kb, and 1,533 kb in the greyhounds, Rottweilers, and IWH, respectively.
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Figure 2 Mixed-model GWAS corrects for population structure and identifies 33 OSA associated loci explaining a large fraction of
phenotype variance. In each breed, the QQ plots show no evidence of stratification relative to the expected distribution, identifying nominal
significance at -log10p of 3.5 and the 95% empirically determined confidence intervals (dashed grey line) at -log10po f(a) 5 in the greyhounds,
(b) 4 in the Rottweilers, and (c) 3.7 in IWH. In the IWH, a plateau of SNPs at P=6.6× 10
-5 corresponds to a 1.65 Mb haplotype on chromosome
18 peaking at the gene GRB10. (d) In greyhounds, 14 loci have P<0.0005, with one locus, on chromosome 11, exceeding 95% confidence intervals
(dashed lines). (e) In Rottweilers, 15 and 6 loci are identified, (f) while only four and two loci are identified in IWHs. (g) For each breed, the phenotype
variance explained by the associated loci, broadly defined by SNPs with r
2 >0.2 within 5 Mb of the peak SNP, exceeds 50%. In greyhounds, the 14
regions explain 56.9% +/− 12.5%, in Rottweilers, 15 regions explain 85.3 +/− 13.6%, and in IWH, four regions explain 53.1 +/− 15.5%. (h) For each
affected dog (red circles) and unaffected dog (black circles), we estimated their relative risk based on the genotypes and odds ratio of the top SNP
from each region for the breed (Table 1), showing that even using a small number of SNPs we see clear differences between the cases and
the controls.
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While the breeds do not segregate for the same risk vari-
ants, their shared predisposition to OS suggests the risk
alleles may disrupt the same cellular pathways. All but
four of the 33 OS associated regions contain known
genes. The majority have just one gene (60%), but a
handful have considerably more, including the top
Rottweiler region (35 genes) and three out of four IWH
Table 1 Osteosarcoma associated loci identified by independent GWAS in three dog breeds with high rates of
the disease
SNP chr Position P Risk
allele
OR f (A) f (U) Region start-end Size
(kb)
Genes
Greyhound
BICF2P133066 11 44405676 6.4E-07 A 1.26 0.84 0.65 44392734-44414985 22 None
BICF2P1421479 8 35448126 3.4E-05 C 1.36 0.12 0.03 35433142-35454649 22 OTX2 (50 kb)
BICF2S23118341 13 14588716 1.1E-04 T 1.20 0.34 0.19 14549973-14645634 96 None
BICF2S23325120 25 21912859 1.3E-04 A 1.19 0.56 0.41 21831580-21921256 90 None
BICF2P66597 14 49193217 1.6E-04 G 1.19 0.37 0.23 48831824-49203827 372 BMPER
BICF2P1194727 5 16085937 1.8E-04 G 1.23 0.28 0.14 16071171-16152955 82 GRIK4
BICF2G63051809 19 34134931 2.8E-04 T 1.21 0.80 0.67 33963105-34145310 182 EN1, MARCO
BICF2G630813090 16 43669044 3.0E-04 C 1.16 0.64 0.48 43665149-43737129 72 MTMR7
BICF2G630418573 15 63780452 3.4E-04 A 1.26 0.91 0.81 63767963-63800415 32 None
TIGRP2P215623 16 40896559 3.5E-04 C 1.36 0.97 0.89 40883517-41081510 198 SGCZ
TIGRP2P331221 25 43485109 3.8E-04 G 1.23 0.22 0.11 43476429-43528145 52 CCL20
BICF2S23516022 1 112990983 3.8E-04 C 1.21 0.82 0.69 112977233-113081800 105 CD3EAP, ERCC1, ERCC2,
FOSB, PPP1R13L
TIGRP2P45171 3 5564882 4.0E-04 T 1.20 0.79 0.68 5162058-6465753 1,304 FER, MAN2A1, PJA2
BICF2P1090686 7 64672328 4.2E-04 C 1.16 0.57 0.43 64631053-64703475 72 CHST9
Rottweiler
BICF2P1115364 1 116524913 5.0E-07 G 1.32 0.71 0.39 115582915-116790630 1,208 Many (35 genes)
BICF2P411325 2 19515571 5.8E-06 C 1.43 0.91 0.73 19212450-19542015 330 KIAA1462
BICF2P1210630 1 122048812 1.1E-05 C 1.30 0.73 0.46 122033806-122051988 18 C19orf40, CEP89, RHPN2
TIGRP2P407733 35 18338700 1.8E-05 A 1.28 0.51 0.29 18326079-18345318 19 None
BICF2P341331 9 47659782 7.6E-05 A 1.28 0.53 0.28 47647012-47668054 21 BLMH, TMIGD1
BICF2P1129874 38 11714169 9.4E-05 T 1.24 0.49 0.26 11252518-11739329 487 FAM5C
TIGRP2P286750 21 46283811 1.1E-04 C 1.37 0.84 0.70 46231985-46363479 131 NELL1
BICF2S23533459 17 14472761 1.3E-04 C 1.39 0.18 0.01 14465884-14482152 16 None
BICF2G630590368 32 25147661 2.7E-04 A 1.35 0.95 0.81 25136302-25156153 20 EMCN
BICF2P92014 36 29651125 3.0E-04 A 1.22 0.66 0.42 29637804-29663408 26 None
TIGRP2P200071 15 38987072 3.1E-04 T 1.27 0.82 0.59 37986345-39974762 1,988 Many (15 genes)
BICF2P1164085 1 29775073 3.3E-04 G 1.24 0.46 0.23 29405587-29914411 509 EYA4, TCF21
BICF2S23712115 26 32385934 3.7E-04 G 1.35 0.91 0.76 32374093-32428448 54 ARVCF, C22orf25, COMT
BICF2G63095567 25 29671618 3.9E-04 G 1.30 0.23 0.05 29658978-29767164 108 XKR6
BICF2P841536 26 3537143 4.2E-04 A 1.26 0.48 0.30 3529343-3550075 21 FBRSL1
Irish Wolfhound
BICF2S23746532 5 15264066 2.1E-05 A 1.40 0.45 0.16 14720254-15466603 746 BLID
BICF2P1466354 18 4937944 2.7E-05 C 1.36 0.56 0.21 4266743-5854451 1,588 C7orf72, COBL, DDC, FIGNL1,
GRB10, IKZF1, VWC2, ZPBP
BICF2P1225386 1 17742179 3.2E-04 C 1.31 0.46 0.19 16768869-18150476 1,382 BCL2, KIAA1468, PHLPP1, PIGN,
RNF152, TNFRSF11A, ZCCHC2
BICF2P1125643 9 19623231 4.3E-04 C 1.75 0.14 0.02 18896060-19633155 737 ABCA5, KCNJ16, KCNJ2, MAP2K6
OR is the conditional odds ratio estimated from beta values calculated by EMMAX.
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Figure 3 Identification of the top associated variant and functional analysis on chromosome 11. (a) We targeted 2.5 Mb around the
greyhound GWAS peak on chromosome 11 for dense sequencing (15 dogs) and finemapping (180 cases and 115 controls). Imputation and
association testing of sequenced variants narrowed the peak of association in greyhounds dramatically to a 15 kb risk haplotype (chr11:44390633–
44406002), telomeric of the genes CDKN2A and CDKN2B, that is nearly fixed in both the Rottweilers (98% in cases and 96% in controls) and IWH (95%
in cases and 92% in controls). (b) The top haplotype (blue vertical lines) maps to a locus downstream of the non-coding gene ANRIL on human
chromosome 9 (hg19). (c) We tiled the human chromosome 9 region with luciferase assays and assayed the function in osteosarcoma cell lines
compared to renilla. Potential markers of function in the region include H3K27 acetylation in osteoblasts and DNase hypersensitivity clusters (assayed
from 125 cell types), most notably in regions that align between the dog and human genomes in a Multiz alignment of 46 species and are
constrained across mammals as measured by Genomic Evolutionary Rate Profiling (GERP) [21-24]. (d) Of the seven non-control luciferase assays,
four (B, C, E, and G) showed a significant increase compared to empty vector. Construct G showed by far the strongest increase with an
approximate 32-fold increased activity suggesting a strong enhancer. (e) This fragment contains one of the top SNPs (Canfam2.0 chr11:44405676)
which has a constrained reference allele C corresponding to a predicted transcription factor binding site, while the OS associated allele, A, is not found
among 29 mammals or the wolf.
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GWAS regions using GRAIL, a statistically robust, web-
based method that uses published scientific abstracts to
find gene relationships connecting distinct genomic re-
gions [37]. We identified significant connectivity be-
tween OS associated regions both within and between
breeds through key terms including ‘bone’ (13 loci),
‘differentiation’ (13 loci), and ‘development’ (9 loci)
(Figure 4a, Additional file 1: Table S4). For example,
OTX2, an oncogenic orthodenticle homeobox protein
that directly activates cell cycle genes and inhibits differ-
entiation in medulloblastomas [38], is strongly associ-
ated with OS in the greyhounds. GRAIL connects OTX2
with genes in six other risk loci (P<0.05): two negative
regulators of osteoblast differentiation BMPER and
VWC2 [39]; EN1, a modulator of osteoblast differenti-
ation and proliferation [40]; DLL3, a notch ligand impli-
cated in human skeletal growth disorders [41]; TCF21,a
tumor suppressor that regulates mesenchymal-epithelial
cell transitions; and EMCN, a mucin-like anti-adhesion
membrane protein and hematopoietic stem cell marker
[42]. In a second network, GRAIL connects three genes
that regulate bone formation - the osteoblast differenti-
ation enhancer FAM5C [43]; NELL1, a regulator of osteo-
blast differentiation and ossification [44]; and TNFRSF11A,
an essential mediator of osteoclast development [45] - and
the pro-apoptotic gene BLID, frequently deleted in human
breast, lung, ovarian, and cervical cancers [46].
Fixed and selected loci in breeds contribute to disease risk
It is likely that alleles that are fixed or at high frequency
in breeds, and thus undetectable by GWAS, contribute
to OS risk, as seen at the CDKNA2/B locus. In each
breed a substantial portion of the genome is comprised
of fixed regions (minor allele frequency <0.05) longer
than 250 kb: 2.8% of the autosomal genome in the
greyhounds, 2.9% in the Rottweilers, and 7.6% in IWH
(Additional file 1: Figure S7a; 25.9%, 30.5%, and 31.5%
for chromosome X). These fixed regions overlap genes
involved in bone development and OS, including RB1
(IWH), FOS (Rottweilers), RUNX2 (Rottweilers), CCNB1
(IWH), COL11A2 (greyhounds), and POSTN (IWH and
greyhounds) [49]. We tested genomic regions fixed in all
three breeds for gene set enrichment using INRICH, em-
pirically measuring significance through 100,000 permu-
tations matched for region size, SNP density, and gene
number [50]. Among eight sets of microRNAs impli-
cated in OS pathobiology [51-55], we found significant
enrichment for one associated with pathogenesis and
progression of OS (5/27 genes, P= 0.017, Pcorrected =
0.041, Additional file 1: Table S6) [51].
We next analyzed the fraction of the genome
that shows exceptionally low variation in OS breeds
compared to 28 other breeds, including regions of
incomplete fixation. We defined these regions of re-
duced relative variability (RRVs) by comparing each OS
breed to up to 28 other dog breeds and focusing on the
1% least variable 150 kb regions [17]. RRVs totaled 2.9%
(277 regions), 2.9% (344 regions), and 3.1% (387 regions)
of the genome in the greyhounds, Rottweilers, and IWH,
respectively (Additional file 1: Figure S7b). We tested
the RRVs for gene set enrichment using INRICH and
combined these P values with those from a matched ana-
lysis of the GWAS regions. We hypothesized that, if genes
in RRVs contribute to OS risk, we should see the same
gene pathways enriched in the two analyses. While, as
expected, the vast majority of gene sets in the studied
breeds showed no increase in significance compared to
the background distribution, seven gene sets are markedly
inflated. This includes three pathways (KIT, p53, and
PDGFRB) in a list curated by the National Cancer Institute
and Nature Publishing Group (Figure 4b) and, from the
Molecular Signatures Database, two gene sets defined by
cis-regulatory motifs - targets of MIR - 124A (TGCCTTA)
and a highly conserved motif with no known transcription
factor match (Figure 4c) [47]. We found only weak P value
inflation in the Gene Ontology analysis (Figure 4d).
GWAS pathways enriched for somatic mutations in
OS tumors
Our analysis of the OS breeds demonstrates that inher-
ited variants are major factors for determining whether a
dog develops OS. As somatic changes in the tumor also
contribute to progression of the disease, we hypothesize
that genes affected by these changes will be enriched in the
same pathways as the inherited variants. We investigated
the frequency and distribution of somatic DNA copy num-
ber aberrations (CNAs) in 22 OS tumor samples (12 grey-
hounds, 10 Rottweilers) using 26 kb-resolution genome-
wide array-based comparative genomic hybridization ana-
lysis (array-CGH).
While the CGH profiles exhibit the extensive karyo-
typic instability characteristic of OS [56], they are re-
markably conserved between the two breeds, with no
significant regional differences in DNA copy number
status (defined as corrected P<0.05; Additional file 1:
Figure S8a,b,c). Moreover, the genome-wide CGH pro-
files of dog and human OS are broadly consistent, both
in the frequency and relative distribution of CNAs
(Additional file 1: Figure S8d), including genes associ-
ated with OS pathogenesis [56], such as MYC gain (60%
in dog/67% in human), RB1 loss (36%/33%), RUNX2
gain (45%/67%), and CDKN2A/B loss (73%/67%).
Using the GISTIC algorithm [57], we identified discrete
regions that had statistically high CNA frequency in canine
tumors relative to the globally chaotic genomic background
of OS, suggestive of specific gene targets strongly associated
with disease pathogenesis. The most significant was a
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Figure 4 Connectivity and enrichment analysis identifies pathways linked to OS in multiple breeds. (a) Most of the associated regions in
each breed contain one or more genes (black text). Genic regions are shown for the greyhounds (blue), IWH (purple), and Rottweilers (red), with
hue alternating between light and dark to distinguish regions, numbered as in Table 1. GRAIL [37] analysis identified non-random connectivity
(P<0.05) between associated genes (bold text), both within breeds (blue, purple, and red arched lines for greyhounds, IWH, and Rottweilers) and
between breeds (grey arched lines). Twelve regions contain genes (blue dots) connected to the key word ‘bone’, one of the top terms identi-
fied by GRAIL (Table S4). (b, c, d) When gene set enrichment P values for the associated regions and regions of reduced variability are com-
bined, most sets shows no inflation compared to background (grey circles; RRV P values from 28 other breeds). However a small number are
inflated, including (b) five from the NCI pathway interaction database [47], (c) two from the Molecular Signatures database of shared cis-
regulatory motif based sets [48], and (d) 0 from the Gene Ontology database. (e) Of the seven gene sets (colors match discovery breed), five
are significantly enriched (bold numbers) in regions that are aberrant in all greyhound (blue), all Rottweiler (red), or all dogs (black) for which
we compared normal and tumor DNA using comparative genomic hybridization. Boxed numbers show number of genes in gene set overlapping
CGH regions; ‘up’ and ‘down’ indicates gain or loss in all samples; ‘any’ indicates all samples are either amplified or deleted.
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encompassing the CDKN2A and CDKN2B genes, with the
strongest signal (Pcorrected=1. 5×10
-12) at chr11:44,304,860-
44,308,340 between CDKN2B and CDKN2A-AS1,a p p r o x i -
mately 100 kb from the top greyhound GWAS SNP. This
region was deleted in 73% of tumors (9/12 greyhounds,
7/10 Rottweilers), of which 59% were consistent with
homozygous deletion (7/12 greyhounds, 6/10 Rottweilers).
No other regions identified by GISTIC overlapped GWAS
loci, reinforcing the fundamental role of the CDKN2A/B
region in disease pathogenesis.
We tested the subset of the CGH samples (7 greyhounds
and 7 Rottweilers) also included in the GWAS analysis and
found that five of the top 29 GWAS SNPs are moderately
associated with tumor gain or loss, most significantly at
the gene BLMH, a candidate tumor suppressor gene for
hepatocellular carcinoma [58] (Additional file 1: Table S5).
Furthermore, certain probes were enriched for genomic
imbalance; the fraction of probes gained or lost in all
Rottweilers (n= 8,087, 4.95%), all greyhounds (n=8, 78 1,
5.35%), or all 14 dogs (n=1,603, 0.98%) was much higher
than expected by random chance (Pbinomial= 2.71%, 1.3%,
and 0.04%, respectively). We found putative human
OS driver genes deleted in human tumors [59] are
among those lost in all greyhounds (ARHGAP22, ARID5B,
RCBTB1;I N R I C He n r i c h m e n tP=0.0004), all Rottweilers
(LHFP; P=0.13), and all dogs (AIFM2,TSC22D1; P= 0.024).
Of the seven gene sets enriched in the GWAS+ RRV
analysis, five are also enriched in the CGH regions in
one or both breeds (Figure 4e). In particular, genes with a
MIR-124A cis-regulatory motif, identified in IWH, showed
significant enrichment in both Rottweiler and greyhound
tumors. MIR-124A has diverse regulatory functions: it is
upregulated during chondrogenesis [60], is a potential si-
lencer of CDK6 when downregulated in leukemia [61], and
regulates NFκB [62]. Except for MIR-124A, gene sets tend
to have stronger enrichment in the greyhounds than in the
Rottweilers. While this could suggest breed-specific OS
pathways, it may also reflect greater tumor heterogeneity
in the Rottweilers diluting the enrichment results.
Discussion
Through a parallel multibreed canine association study,
we found 33 genomic regions associated with OS, and
identified genes and pathways potentially causing this
complex, polygenic, and poorly understood disease.
Altogether, the 33 loci identified by GWAS account for
50% to 80% of the disease risk within each of these three
breeds, demonstrating that inherited factors are the pre-
dominant cause. In addition, regions of unusually low
variability, reflective of the small effective population
sizes and strong artificial selection used to create dog
breeds, are also likely to contribute to an overall in-
creased risk for these breeds.
None of the OS GWAS loci overlapped between breeds,
a strikingly different genetic architecture from the shared
variants previously found by mapping Mendelian traits in
multiple dog breeds. Potentially this could reflect the dif-
ference between: (1) a monogenic trait, where a single
variant causes a trait, which, if desirable, is then deliber-
ately bred for; and (2) a complex trait, caused by a random
assortment of many low frequency risk factors that rise in
frequency through population bottlenecks and selection.
This latter scenario is more similar to the genetics in hu-
man populations, where many rare risk factors may
underlie OS, and may increase in frequency by random
drift or moderate natural selection. In dog breeds, tighter
bottlenecks and stronger selective forces push risk allele
frequencies up, making them easier to detect. Thus, dogs
bring added value to the study of OS.
The relatively large number of OS associated genes
identified in this study facilitated pathway analysis with
two different methods. First, the GRAIL software, given
only the human genomic regions syntenic to the dog
GWAS loci as input (and no information on phenotype)
mined the abstracts of all previously published literature
and found significant connections between associated genes
related to growth, osteoblast differentiation and prolifera-
tion, and tumor suppression. Furthermore, a combined
gene set enrichment analysis of the associated, fixed,
and somatically altered loci identified common pathways
affected by inherited and somatically acquired variation,
suggesting they may interact to cause tumor initiation and
progression. A fraction of the genes and pathways identified
have previously been reported to be involved in human OS
as either inherited or somatic changes, demonstrating the
relevance of the canine model. Potentially more interesting,
we also identified novel pathways, including two related to
poorly characterized cis-regulatory motifs.
The GWAS loci implicated, several of which contain
no known genes, show that canine OS has a complex
genetic architecture with key advantages over artificially
induced mouse models of the human disease. This is
well illustrated by our functional analysis of the top
greyhound locus. The strong effect of the variant and
low genetic diversity of the breed populations allowed us
to move rapidly from GWAS region to candidate func-
tional variants with limited additional sequencing and
genotyping. The top candidate causal variant is in a non-
coding regulatory element upstream of the CDKNA2A/B
locus, near, but not overlapping, a region associated with
canine histiocytic sarcoma [63]. Pinpointing functional
regulatory variants is harder than finding functional cod-
ing variation, but such regulatory variation is likely more
representative of the genomic variants underlying com-
mon human diseases [64].
The CDKNA2A/B locus in dogs is syntenic to the hu-
man 9p21 locus, one of the most complex regulatory loci
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nificantly and independently associated with diseases in-
cluding coronary artery disease, myocardial infarction,
type 2 diabetes, melanoma, basal cell carcinoma, glioma,
acute lymphoblastic leukemia, and breast cancer [64].
Deciphering the cellular mechanisms disrupted by OS
associated regulatory variation in dogs may elucidate
mechanisms underlying diverse human diseases.
We hypothesize that the top canine OS risk variant at
chr11:44405676 alters regulation of CDKN2A/ARF. The
OS associated variant at dog chr11:44405676 disrupts a
highly constrained position in a genomic locus that we
show, using a luciferase assay, has strong enhancer activ-
ity in a human osteosarcoma cell line. CDKN2A/ARF en-
codes the INK4 family of cyclin-dependent kinase
inhibitor proteins (including p16
INK4a, p15
INK4b, and
p14ARF). These proteins control G1-progression by in-
activation of D-cyclins, inducing senescence via the RB
and p53 pathways [65-67]. Altered levels of CDKN2A, a
master regulator of tissue development, are linked to
hematopoietic stem cell senescence and development,
key feature of malignancies including OS [68,69]. SNPs
that disrupt enhancer element binding can change tran-
scriptional activity across the human 9p21 locus, including
at CDKN2A [36]. Germline variants affecting regulation of
CDKN2A may alter the balance between proliferation and
senescence in specific tissues, thereby leading to an in-
creased risk of developing OS and potentially also other
cancers in adolescence and adulthood.
Canine and human OS are remarkably similar diseases,
both clinically [8] and in their tumor gene expression
profiles [6,7]. The recent publication of the first GWAS
of osteosarcoma in humans offers a new opportunity to
identify common risk factors shared between the two
species and thus of particular etiological interest. The
human OS GWAS compared 941 patients with osteosar-
coma to 3,291 unaffected adults across 699,000 SNPs
and found two genome-wide significant loci, one at the
glutamate receptor gene GRM4 and the other in a gene
desert [5]. The much larger dataset required for GWAS
in human patients illustrates the power offered by map-
ping in genetically isolated dog breed populations. While
we see no association in the dog GWAS at the two loci
found in the human GWAS, another glutamate receptor
gene (GRIK4) is associated with OS in greyhounds. Al-
though glutamate signaling in primary bone cancers is
not well understood, both GRM4 and GRIK4 are
expressed in normal bone, and glutamate signaling has
been shown to regulate bone formation and resorption
[70]. Furthermore, inhibition of glutamate receptors
limits cell growth in many cell lines.
The association of glutamate receptors with OS in both
dogs and humans suggests glutamate signaling as a poten-
tial therapeutic target, although the diverse physiological
functions of this pathway could make this difficult. Gluta-
matergic signaling is critical for learning and memory
[71] and is implicated in a range of neuropsychiatric dis-
eases in both humans [72-74] and dogs [75]. Fixation of
variants in glutamate related genes, as seen near GRM4 in
Rottweilers (Additional file 1: Figure S9), may suggest that
selection on behavioral, as well morphological, traits
helped drive OS to the exceptionally high rates seen in
the breeds studied here.
Conclusions
Detailed characterization of the genetic risk factors in-
volved in initiation and progression of canine OS will
give us a comprehensive understanding of the genes in-
volved and the different genetic interactions sufficient to
cause the disease. We hypothesize that, by integrating
genetic etiology into canine clinical trials, we can iden-
tify molecular subtypes of OS and correlate them with
treatment efficacy and survival outcomes. In the future,
we anticipate that the insights gained from the canine
model will help us develop more personalized and effect-
ive treatments for human OS.
Methods
Sample collection and genotyping
DNA samples used were collected from pet dogs with
the owner’s consent. Osteosarcoma was diagnosed by a
qualified veterinarian using X-ray and/or tumor histo-
pathology. Histological subtype was not included in
GWAS analysis because of the difficulty of ascertaining
it consistently across diverse collection sites. Osteosar-
coma can be reliably diagnosed without histopathology
in breeds with exceptionally high rates of the disease.
Dogs classified as unaffected had no history of cancer.
Phenotype included age at disease onset for most (79%)
of affected dogs. For almost all (98%) of unaffected dogs,
phenotype included age last confirmed OS free. Samples
were collected with the appropriate consent and animal
care protocols (U Minn 0802A27363, 1101A94713, and
MIT 0910-074-13). Genomic DNA was isolated from
whole blood (QIAamp DNA Midi kit) and was genotyped
for approximately 170,000 SNPs using the Illumina 170 K
canine HD array [17].
Data analysis
SNPs and individuals with genotyping rate <0.95 were re-
moved with PLINK [35]. Genetic relatedness and principal
component (PC) analysis was done with GCTA [76]. To
minimize population structure in the GWA analysis
within each breed, we removed one dog from each con-
cordant phenotype pair with genetic relatedness >0.25,
preferentially retaining the younger case and older control.
We measured phenotype-genotype association with the
mixed model method implemented in EMMAX [77],
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significance of the slope coefficient by the standard t test
[77]. We included the top PC as a covariate to control for
remaining cryptic relatedness [18].
We defined genome-wide significance in the GWAS
using empirical 95% confidence intervals (CIs) rather
than using a Bonferroni correction. As previously noted,
a Bonferroni correction for the number of SNPs tested is
excessively stringent in dog breeds, where extensive LD
means that each SNP is not an independent test [14]. Of
the approximately 100,000 SNPs used in the GWAS, the
majority (98%) are in LD (r2 >0.5) with at least one
other SNP within 1 Mb, and most (60%) are in LD with
10 or more SNPs. While an alternative is to correct for
the number of independent haplotype blocks (if haplo-
type blocks are 1 Mb [14], the 2.4 Gb genome is com-
prised of roughly 2,400 independent haplotype blocks,
corresponding to a corrected genome-wide significance
threshold of 2 ×10
-5), accurately determining the num-
ber of independent genomic regions in a particular breed
population is difficult. We defined genome-wide signifi-
cance using 95% CIs calculated from the empirical dis-
tribution of P values observed in the absence of real
association. We determined this distribution by rerun-
ning the GWAS with randomly permuted phenotypes
1,000 times. Conceptually, the empirical CIs bound the
area in which 95% of the permutation QQ plots fall. We
note that in dog breeds, the empirical CIs set more con-
servative thresholds than the CIs for a uniform score
distribution used in, for example, human GWAS studies
[78] (Additional file 1: Figure S10). We defined genome-
wide significance as associations exceeding the 97.5%
upper empirical CI, a threshold that varies by breed (1×
10
-5 in Greyhounds, 1 × 10
-4 in Rottweilers, and 2 ×10
-4
in IWH; Figure 2).
We defined genome-wide significant associations as
those exceeding the 97.5% upper CI. To facilitate gene
set and pathway analysis, we also identified a larger set
of candidate OS regions with P<0.0005. The laxer
threshold encompasses associations exceeding the theor-
etical CIs but not necessarily the stricter empirical CIs.
We note that the inflated P values suggest that these re-
gions are enriched for true OS associations. Although
some of the regions included may not be true associa-
tions, this would most likely weaken rather than
strengthen the gene set and pathway analyses, leading to
false negatives rather than false positives.
We used linkage disequilibrium clumping in PLINK to
define regions of association in two stages, first defining
wide regions of SNPs in weak LD (r2 >0.2 within 5 Mb
of top SNP) and then narrowing the association to a single
peak of SNPs in strong LD (r2 >0.8 within 1 Mb of top
SNP). While potentially masking a small number of
true disease associated variants, this conservative approach
ensured we identified only the strongest peaks and not
regions with association reflecting proximity to a stronger
peak. For each breed, we used GCTA to estimate the
phenotype variance explained by the associated loci, which
we defined broadly as SNPs with r
2 >0.2 within 5 Mb of
the peak SNP, totally 36.4 Mb for greyhound, 58.5 Mb for
Rottweilers, and 18 Mb for IWH.
Sequencing of top locus
We resequenced 5.9 Mb (chr11:43,000,000-48,900,000)
in eight greyhound cases and seven controls using a
Roche Nimblegen sequence capture array comprised of
385,000 probes covering approximately 95% of the target
region. After library preparation (Illumina Paired end
kit) DNA was hybridized to the array following the man-
ufacturer’s protocol and the enriched samples sequenced
using paired-end sequencing (2 ×74 bp) on the Illumina
Genome analyzer II. Sequence reads were aligned to the
CanFam2 genome reference using BWA [79]. Picard
[80] was used to identify and mark duplicate reads (PCR
artifacts) and the Genome analysis toolkit [81,82] to re-
calibrate quality scores, local realignment around indels,
and call SNPs and indels. Variants were filtered based on
sequence depth, quality of alignments, SNP clusters, and
strand bias. In total, we identified 16,475 high quality vari-
ants; the Ts/Tv ratio was 2.06. The variants were anno-
tated for cross-species conservation using SEQscoring
[83,84], annotated and analyzed for predicted effect by
using snpEff [85], and were visually examined by IGV [86].
We genotyped variants discovered in the sequence
data using the Sequenom iPLEX Massarray system, tiling
the center of the associated region (chr11:44.35 -
44.47 Mb) most densely. We genotyped 124 SNPs in
greyhounds (172 A+110 U) and Rottweilers (64 A+32 U)
and 60 SNPs in IWH (22 A+30 U). SNPs were prioritized
for genotyping if they were located in a protein coding
sequence as defined by SnpEff [84] or in a conserved
element compared to 29 other mammals [87]. We used
Beagle 3.3.2 [88] to imputed genotype for all sequenced
variants in LD with a genotyped variant (r2 >0.75) in the
greyhounds and tested for association using PLINK [35].
We analyzed 41 bases around the top candidate SNP in
greyhound for transcription factor binding motifs using
FIMO [31] (JASPAR, UniPROBE, ENCODE-motifs data-
bases, P value <1e-4) and TOMTOM [32] (JASPAR and
UniPROBE databases, E-value <10) testing both the OS
risk and non-risk alleles.
Enhancer assay
For the enhancer assay, potential enhancer regions were
PCR amplified from human gDNA and placed in front
of minimal promoter driven luciferase reporter gene
(pGL4.26, Promega). HTB-96 U-2 OS osteosarcoma cells
were obtained from American Type Culture Collection
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purchase (February 2013). All cells were authenticated
by standard ATCC procedures [89]. U-2 OS cells were
seeded in 96 well plates (25,000 cells/well) and grown
for 20 to 26 h before transfection. Each well was trans-
fected with 0.1 μg reporter construct and 0.01 μg renilla
luciferase driven by CMV promoter to control for cell
density, using 0.4 μL/well FuGENE (Promega) according
to the manufacturer’s instructions. Twenty-four hours
after transfection, luciferase activity was measured sequen-
tially using the Dual-Glo Luciferase System (Promega)
using a Synergy H4 hybrid reader (BioTek). At least three
independent experiments were performed, each with eight
technical replicates of every construct.
Pathway analysis
GRAIL analysis, using the PubMed Text (Aug2012) data
source, was run on the OS regions (Table 1) lifted over
to human genome hg18 coordinates (genome.ucsc.edu/
cgi-bin/hgLiftOver) with 50 kb flanks added to start and
end and gene size correction turned on. Gene set enrich-
ment testing was done with INRICH, empirically measur-
ing significance through 100,000 permutations matched
for region size, SNP density, and gene number [50].
INRICH reports the significance for each gene set (P), and
the experiment-wide significance correcting for the num-
ber of gene sets tested (Pcorr); thus, the correction varies
depending on the number of sets included in the analysis.
We considered Pcorr <0.05 to be significant. We tested
gene sets between 10 and 2,000 genes from five catalogs:
three MSigDB collections (c2, c3, and c4 with 2593, 819,
and 836 gene sets, respectively from [90]); the Gene
Ontology ([91]; 1,582 sets); and the NCI/Nature pathway
interaction database ([92]; 166 sets). We also made a cus-
tom catalog of putative osteosarcoma driver genes based
on a recent publication [59]. We ran INRICH on canFam2
using a map file of 17,665 genes lifted over from the hg19
RefSeqGene catalog (UCSC Genome Brower) [93]. We
made a custom catalog of 10 microRNA sets associated
with OS in recent papers [51-55] and ran INRICH with a
canFam2 map file of 532 human microRNAs mapped to
dog with liftOver (Additional file 1: Table S6).
For each gene set we calculated the combined enrich-
ment P value from the INRICH empirical P values for
the GWAS and RRV regions using Fisher’s combined
probability test. We first calculated the scores for each
GWAS breed (that is, greyhound GWAS enrichment P
combined with greyhound RRV enrichment P). We then
determined the expected background distribution by
doing the same using RRV enrichment test for each of a
panel of 28 reference breeds, and then combining the
GWAS enrichment P from each of the three GWAS
breeds with the RRV enrichment P from each of the
non-GWAS breeds [17].
CGH
CGH analysis of primary canine OS was performed as
described previously [94] using an approximate 180,000
feature Agilent canine oligonucleotide CGH array with
approximately 26 kb resolution within the canFam 2.0
genome sequence assembly. An equimolar pool of con-
stitutional DNA from 50 female dogs of mixed breed
was used as the common reference for all OS cases. Ar-
rays were scanned at 3 μm resolution using an Agilent
G2565CA scanner and image data were processed using
Feature Extraction version 10.10 and Genomic Work-
bench version 7.0 (Agilent Technologies) to exclude
probes exhibiting non-uniform hybridization or signal
saturation. Recurrent CNAs within each tumor were de-
fined using the FASST2 segmentation algorithm in
Nexus Copy Number version 6.1 (Biodiscovery Inc.)
based on a minimum of three consecutive probes with
log2 tumor:reference values ≥0.2 (copy number gain)
or≤−0.2 (copy number loss). We compared genotypes
at the top GWAS SNPs in Greyhound and Rottweiler
(Table 1) to the CGH data from tumors for seven case
greyhounds and seven case Rottweilers by first defining,
for each probe, each dog’s phenotype (gain =log2 tumor:
reference values ≥0.2 and loss =log2 tumor:reference
values ≤0.2) and then associating phenotype with geno-
type using the Cochran-Mantel-Haenszel test in PLINK
to control for breed clusters.
Data availability
The data presented in this publication are available
through the Gene Expression Omnibus (accession num-
ber GSE52147) and ArrayExpress (accession numbers
E-MTAB-1984 and E-MTAB-1986). Datasets analyzed in
the paper are also available at [95].
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